{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:40:46Z","timestamp":1793047246148,"version":"4.5.0"},"reference-count":14,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1136\/thorax-2025-224636","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:20:20Z","timestamp":1774632020000},"page":"1102-1105","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Inhaled corticosteroid withdrawal and mortality rate in trials of triple therapy inhalers for COPD"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6510-8573","authenticated-orcid":false,"given":"Kari","family":"Leung","sequence":"first","affiliation":[{"name":"UCL Hospitals NHS Foundation Trust, London, UK"},{"name":"University College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-0081","authenticated-orcid":false,"given":"Aroon D","family":"Hingorani","sequence":"additional","affiliation":[{"name":"UCL Hospitals NHS Foundation Trust, London, UK"},{"name":"University College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026102613101896000_81.11.1102.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916046"},{"key":"2026102613101896000_81.11.1102.2","unstructured":"Breztri aerosphere\u00ae promotional material (us-68433 10\/22)."},{"key":"2026102613101896000_81.11.1102.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202006-2618OC"},{"key":"2026102613101896000_81.11.1102.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901"},{"key":"2026102613101896000_81.11.1102.5","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in All-Cause Mortality with Fluticasone Furoate\/Umeclidinium\/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026102613101896000_81.11.1102.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202312-2311OC"},{"key":"2026102613101896000_81.11.1102.7","unstructured":"MedCalc Software Ltd . Comparison of proportions. Available: https:\/\/www.medcalc.org\/en\/calc\/comparison_of_proportions.php [Accessed 22 Jan 2026]."},{"key":"2026102613101896000_81.11.1102.8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(21)00238-1","article-title":"Perplexing mortality data from triple therapy trials in COPD","volume":"9","author":"Suissa","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026102613101896000_81.11.1102.9","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.034280"},{"key":"2026102613101896000_81.11.1102.10","unstructured":"Welsh ET . FDA advisory panel does not back mortality risk-reduction update to Trelegy Ellipta label. Healio [internet]. 2020. Available: https:\/\/www.healio.com\/news\/pulmonology\/20200831\/fda-advisory-panel-does-not-back-mortality-riskreduction-update-to-trelegy-ellipta-label [Accessed 22 Jan 2026]."},{"key":"2026102613101896000_81.11.1102.11","unstructured":"US Food and Drug Administration . Warning letter: AstraZeneca Pharmaceuticals LP re: NDA 212122 Breztri Aerosphere. MARCS-CMS 664789 [internet]. 2023. Available: https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/astrazeneca-pharmaceuticals-lp-664789-08042023 [Accessed 22 Jan 2026]."},{"key":"2026102613101896000_81.11.1102.12","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the prevention, diagnosis and management of chronic obstructive pulmonary disease: 2025 report [Internet]. Fontana (WI): GOLD. 2025. Available: https:\/\/goldcopd.org\/2025-gold-report\/ [Accessed 22 Jan 2026]."},{"key":"2026102613101896000_81.11.1102.13","doi-asserted-by":"crossref","DOI":"10.1080\/15412555.2025.2517622","article-title":"Pharmacologic Treatment of COPD: Disparities Between Evidence and Recommendations in GOLD 2023\/4","volume":"22","author":"Suissa","year":"2025","journal-title":"COPD"},{"key":"2026102613101896000_81.11.1102.14","unstructured":"ClinicalTrials.gov . A study evaluating the efficacy of budesonide, glycopyrronium and formoterol fumarate metered dose inhaler on cardiopulmonary outcomes in chronic obstructive pulmonary disease (THARROS) [Internet]. NCT06283966. Bethesda (MD): National Library of Medicine. 2024. Available: https:\/\/www.clinicaltrials.gov\/study\/NCT06283966?term=Tharros&rank=1 [Accessed 22 Jan 2026]."}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-224636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:10:32Z","timestamp":1793045432000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-224636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1136\/thorax-2025-224636"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-224636","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}